{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T10:57:43Z","timestamp":1768647463686,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jpba.2021.114402","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T16:33:33Z","timestamp":1632933213000},"page":"114402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Development and validation of an HPLC-MS\/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue"],"prefix":"10.1016","volume":"207","author":[{"given":"Ignace C.","family":"Roseboom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bas","family":"Thijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel B.M.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.C.","family":"Dorlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2021.114402_bib1","unstructured":"Paladin Therapeutics, Impavido Package, Reference ID: 3473184, US Food Drug Adm., 2014."},{"key":"10.1016\/j.jpba.2021.114402_bib2","unstructured":"J. Engel, Miltefosine, the story of a successful partnership: disease endemic country - TDR - pharmaceutical industry (Zentaris), TDR News, 2002, 5. \u3008http:\/\/www.who.int\/tdr\/publications\/documents\/tdrnews-issue-68.pdf\u3009."},{"key":"10.1016\/j.jpba.2021.114402_bib3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/01.inf.0000066877.72624.cb","article-title":"Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis","volume":"22","author":"Sundar","year":"2003","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.jpba.2021.114402_bib4","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for indian Visceral Leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2021.114402_bib5","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/ciy747","article-title":"Pharmacokinetics, safety, and efficacy of an allometric miltefosine regimen for the treatment of Visceral Leishmaniasis in Eastern African children: an open-label, Phase II clinical trial","volume":"68","author":"Mbui","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2021.114402_bib6","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1086\/322689","article-title":"Treatment of American cutaneous Leishmaniasis with miltefosine, an oral agent","volume":"33","author":"Soto","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2021.114402_bib7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.pt.2003.09.008","article-title":"Leishmaniasis \u2013 current chemotherapy and recent advances in the search for novel drugs","volume":"19","author":"Croft","year":"2003","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.jpba.2021.114402_bib8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2021.114402_bib9","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1007\/s00216-017-0223-z","article-title":"Miltefosine: a novel internal standard approach to lysophospholipid quantitation using LC-MS\/MS","volume":"409","author":"Godfrey","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2021.114402_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4155\/bio.16.7","article-title":"LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma","volume":"8","author":"Jaiswal","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2021.114402_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jchromb.2008.02.005","article-title":"Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography\u2013tandem mass spectrometry","volume":"865","author":"Dorlo","year":"2008","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2021.114402_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jpba.2016.12.012","article-title":"Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples","volume":"135","author":"Kip","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114402_bib13","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1128\/AAC.02976-15","article-title":"Validation and clinical evaluation of a novel method to measure miltefosine in Leishmaniasis patients using dried blood spot sample collection","volume":"60","author":"Kip","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2021.114402_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchromb.2015.06.017","article-title":"Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry","volume":"998\u2013999","author":"Kip","year":"2015","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2021.114402_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jchromb.2016.07.042","article-title":"Pharmacokinetics and bioavailability assessment of miltefosine in rats using high performance liquid chromatography tandem mass spectrometry","volume":"1031","author":"Valicherla","year":"2016","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2021.114402_bib16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40262-016-0467-3","article-title":"Lack of clinical pharmacokinetic studies to optimize the treatment of neglected tropical diseases: a systematic review","volume":"56","author":"Verrest","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2021.114402_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/cts.12448","article-title":"Importance of drug pharmacokinetics at the site of action","volume":"10","author":"Rizk","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jpba.2021.114402_bib18","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.4155\/bio.12.252","article-title":"Bioanalysis of drug in tissue: current status and challenges","volume":"4","author":"Xue","year":"2012","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2021.114402_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113590","article-title":"Skin tissue sample collection, sample homogenization, and analyte extraction strategies for liquid chromatographic mass spectrometry quantification of pharmaceutical compounds","volume":"191","author":"Roseboom","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114402_bib20","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.4155\/bio.13.209","article-title":"Challenges of atypical matrix effects in tissue","volume":"5","author":"Ho","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2021.114402_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.aca.2016.09.039","article-title":"Investigation of the \u201ctrue\u201d extraction recovery of analytes from multiple types of tissues and its impact on tissue bioanalysis using two model compounds","volume":"945","author":"Yuan","year":"2016","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jpba.2021.114402_bib22","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on Bioanalytical Method Validation, 2012. doi: EMEA\/CHMP\/EWP\/192217\/2009."},{"key":"10.1016\/j.jpba.2021.114402_bib23","unstructured":"Food and Drug Administration, Guidance for Industry Bioanalytical Method Validation Guidance for Industry Bioanalytical Method Validation Center for Veterinary Medicine (CVM), Contains Nonbinding Recommendations, 2013."},{"key":"10.1016\/j.jpba.2021.114402_bib24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchromb.2015.06.017","article-title":"Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry","volume":"998\u2013999","author":"Kip","year":"2015","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2021.114402_bib25","unstructured":"C.T.R. India, New Treatment Regimens for Treatment of Post Kala Azar Dermal Leishmaniasis Patients in India and Bangladesh Region, New Delhi Database Publ. (India). Identifier CTRI\/2017\/04\/008421, 2017, 7. \u3008http:\/\/ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=18509\u3009. (Accessed 26 February\u00a02021)."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521005136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521005136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:15:38Z","timestamp":1760001338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521005136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":25,"alternative-id":["S0731708521005136"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114402","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an HPLC-MS\/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114402","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114402"}}